Literature DB >> 18787380

Absence of allelic imbalance involving EMSY, CAPN5, and PAK1 genes in papillary thyroid carcinoma.

M Hidalgo1, M E Saez, F J Martinez-Tello, F J Moron, E Ferrero-Herrero, M Labalde-Martinez, D Rigopoulou, C Ballestin-Carcavilla, A Ruiz, J L Royo, R Ramirez-Lorca.   

Abstract

Papillary thyroid cancer (PTC) accounts for 80% of all thyroid malignancies, and genetic alterations associated to its etiology remain largely unknown. Chromosomal band 11q13 seems to be one of the most frequently amplified regions in human cancer, providing several candidate genes that need detailed characterization. The aim of our study was to investigate the existence of allelic imbalance at EMSY, CAPN5, and PAK1, as candidate genes within 11q13.5-q14 region using a single nucleotide polymorphism-based analysis. We selected a panel of 9 polymorphisms that were analyzed in 41 thyroid carcinoma samples, their contralateral non-pathological tissue and 178 controls from the general population. We did not detect allelic imbalance at these loci in our series. However, we observed a difference in the EMSY-haplotype distribution among PTC patients when compared to controls (odds ratio=2.00; p=0.02). We conclude that 11q13.5-q14 is not imbalanced in PTC, but there is evidence suggesting that EMSY might be of relevance in PTC etiology.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18787380     DOI: 10.1007/BF03345613

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  27 in total

1.  EMSY, a BRCA-2 partner in crime.

Authors:  David M Livingston
Journal:  Nat Med       Date:  2004-02       Impact factor: 53.440

2.  Genome-wide appraisal of thyroid cancer progression.

Authors:  Volkert B Wreesmann; Ronald A Ghossein; Snehal G Patel; Charles P Harris; Erik A Schnaser; Ashok R Shaha; R Michael Tuttle; Jatin P Shah; Pulivarthi H Rao; Bhuvanesh Singh
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

3.  Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity.

Authors:  Zhaowen Zhu; Raffaele Ciampi; Marina N Nikiforova; Manoj Gandhi; Yuri E Nikiforov
Journal:  J Clin Endocrinol Metab       Date:  2006-06-13       Impact factor: 5.958

Review 4.  Chromosomal alterations in squamous cell carcinomas of the head and neck: window to the biology of disease.

Authors:  S M Gollin
Journal:  Head Neck       Date:  2001-03       Impact factor: 3.147

5.  Specific haplotypes of the RET proto-oncogene are over-represented in patients with sporadic papillary thyroid carcinoma.

Authors:  F Lesueur; M Corbex; J D McKay; J Lima; P Soares; P Griseri; J Burgess; I Ceccherini; S Landolfi; M Papotti; A Amorim; D E Goldgar; G Romeo
Journal:  J Med Genet       Date:  2002-04       Impact factor: 6.318

6.  Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations.

Authors:  Zhaowen Zhu; Manoj Gandhi; Marina N Nikiforova; Andrew H Fischer; Yuri E Nikiforov
Journal:  Am J Clin Pathol       Date:  2003-07       Impact factor: 2.493

7.  Specific pattern of RAS oncogene mutations in follicular thyroid tumors.

Authors:  V Vasko; M Ferrand; J Di Cristofaro; P Carayon; J F Henry; C de Micco
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

8.  Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase.

Authors:  L Adam; R Vadlamudi; S B Kondapaka; J Chernoff; J Mendelsohn; R Kumar
Journal:  J Biol Chem       Date:  1998-10-23       Impact factor: 5.157

9.  A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns].

Authors:  S A Hundahl; I D Fleming; A M Fremgen; H R Menck
Journal:  Cancer       Date:  1998-12-15       Impact factor: 6.860

10.  Common variation in EMSY and risk of breast and ovarian cancer: a case-control study using HapMap tagging SNPs.

Authors:  Patrick R Benusiglio; Fabienne Lesueur; Craig Luccarini; Joan McIntosh; Robert N Luben; Paula Smith; Alison Dunning; Douglas F Easton; Bruce A J Ponder; Paul D Pharoah
Journal:  BMC Cancer       Date:  2005-07-19       Impact factor: 4.430

View more
  5 in total

Review 1.  The function of EMSY in cancer development.

Authors:  Jing Hou; Ziliang Wang; Lina Yang; Xiaomao Guo; Gong Yang
Journal:  Tumour Biol       Date:  2014-03-09

2.  EMSY promoted the growth and migration of ovarian cancer cells.

Authors:  Xiaohong Zhao; Yan Zhou; Mingchao Nie; Saiqiong Xian; Huli Chen; Yingmei Wen; Linjing Zhang; Yumin Huang; Mingfa Chen; Shaosheng Wang
Journal:  Tumour Biol       Date:  2014-12-16

3.  Potentially functional polymorphisms in PAK1 are associated with risk of lung cancer in a Chinese population.

Authors:  Mingfeng Zheng; Jia Liu; Meng Zhu; Rong Yin; Juncheng Dai; Jie Sun; Wei Shen; Yong Ji; Guangfu Jin; Hongxia Ma; Jing Dong; Lin Xu; Zhibin Hu; Hongbing Shen
Journal:  Cancer Med       Date:  2015-09-17       Impact factor: 4.452

4.  Clinical importance of the EMSY gene expression and polymorphisms in ovarian cancer.

Authors:  Agnieszka Dansonka-Mieszkowska; Lukasz M Szafron; Joanna Moes-Sosnowska; Mariusz Kulinczak; Anna Balcerak; Bozena Konopka; Magdalena Kulesza; Agnieszka Budzilowska; Martyna Lukasik; Urszula Piekarska; Iwona K Rzepecka; Joanna Parada; Renata Zub; Barbara Pienkowska-Grela; Radoslaw Madry; Jan K Siwicki; Jolanta Kupryjanczyk
Journal:  Oncotarget       Date:  2018-04-03

5.  Calpain-5 gene expression in the mouse eye and brain.

Authors:  Kellie Schaefer; MaryAnn Mahajan; Anuradha Gore; Stephen H Tsang; Alexander G Bassuk; Vinit B Mahajan
Journal:  BMC Res Notes       Date:  2017-11-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.